Orca Bio’s TREGZI enters the transplant market with a strong Phase 3 advantage
See how Orca Bio’s TREGZI FDA approval could reshape blood cancer transplants, reduce chronic GVHD and test cell therapy scale-up.
Pharma & Biotech
Pharma & Biotech
Can TScan’s TSC-101 Phase 1 data justify a pivotal leap as TCRX stock falls?
TSC-101 produced rapid donor chimerism with a commercial-ready manufacturing process, but TScan must still prove that the cellular therapy prevents post-transplant relapse.